- Current report filing (8-K)
February 28 2012 - 11:51AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act 1934
Date of Report (date of earliest event reported):
February 22, 2012
American Oriental Bioengineering, Inc.
(Exact name of registrant as specified in charter)
Nevada
(State or other jurisdiction of incorporation)
001-32569
|
84-0605867
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
Beijing Economic and Technology Development
Zone
1 First Liangshuihe Street
E-town, Beijing 100176
People’s Republic of China
(Address of principal executive offices
and zip code)
011-86-451-8666-6601
(Registrant's telephone number including
area code)
(Registrant's former name or former address,
if changed since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
£
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On
February 22, 2012,
the Board of Directors of American Oriental Bioengineering Inc. (the “Company”)
approved the appointment of Mr. Yan Gao, age 40, as Chief Accounting Officer (“CAO”) of the Company.
Prior to being appointed as CAO on February
22, 2012, Mr. Gao was an in-house senior accountant for the Company on the financial reporting team, preparing draft reports and
responsible for overseeing financial management matters. He joined the Company in 2006 as the Financial Controller for Guangxi
Lingfeng Pharmaceutical Ltd., a wholly owned subsidiary of the Company, and served as the General Manager of the Company’s
Finance Department in 2009, during which he was in charge of financial planning, cash flow management, internal control compliance,
business consolidations and reporting. Mr. Gao graduated with a major in Accounting from Heilongjiang College with a professional
certificate in 1994.
Mr.
Gao
has no family relationships with any of the executive officers or directors of the Company. There have been no transactions
in the past two years to which the Company or any of its subsidiaries was or is to be a party, in which he has had, or will have,
a direct or indirect material interest.
In addition, Mr. Yang
Yang’s resignation from his position as Chief Marketing Officer of the Company was officially accepted by the Board. Mr.
Yang resigned on February 22, 2012 in order to pursue other personal interests.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AMERICAN ORIENTAL BIOENGINEERING, INC.
|
|
By:
/s/ Tony Liu
|
|
Name: Tony Liu
|
|
Title: Chairman and Chief Executive Officer
|
Dated: February 28, 2012
American Oriental Bioengineering, Inc. (NYSE:AOB)
Historical Stock Chart
From Aug 2024 to Sep 2024
American Oriental Bioengineering, Inc. (NYSE:AOB)
Historical Stock Chart
From Sep 2023 to Sep 2024